Eprex 0.4ml Vials
PDF Leaflet Revision Date: 27 July 2012
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of anaemia in chronic renal failure and cancer patients receiving chemotherapy.
Dosage (summary)
IV: 50 IU/kg 3x/week; SC: 150 IU/kg 3x/week or 40,000 IU weekly for cancer patients.
Onset of Action / Duration
Onset: 2 weeks, Duration: variable
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use with caution; not recommended in pregnant/lactating women.
Key Drug Interactions
- Cyclosporin
- Ferrous sulphate
Contraindications
- Uncontrolled hypertension
- Hypersensitivity to mammalian products
- Myeloid malignancies
Common side effects
- Hypertension
- Nausea
- Headache
- Diarrhoea
Counselling Points
- Monitor haemoglobin levels
- Ensure adequate iron supplementation
- Report unusual headaches
Serious warnings
- Monitor blood pressure closely
- Risk of thromboembolic events
- Caution in patients with seizures
Important Disclaimer
The Eprex 0.4ml Vials professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
